Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb 24;5:170.
doi: 10.1186/s40064-016-1762-z. eCollection 2016.

Steroids, Lidocain and Ioxaglic Acid Modify the Viscosity of Hyaluronic Acid: In Vitro Study and Clinical Implications

Affiliations
Free PMC article

Steroids, Lidocain and Ioxaglic Acid Modify the Viscosity of Hyaluronic Acid: In Vitro Study and Clinical Implications

Thierry Conrozier et al. Springerplus. .
Free PMC article

Abstract

Background: Viscosupplementaion by intra-articular injection of hyaluronic acid (HA) is a therapeutic modality for treating osteoarthritis of the knee, of the hip and less frequently of other joints. During viscosupplementation, it is usual to inject other drugs, without knowing whether this association may have a deleterious effect thereon. The rheological properties of a viscosupplement are highly dependent on the product [molecular weight × concentration] of HA. Therefore, any reduction of its viscoelastic properties is related either to a decrease of its concentration or/and of its molecular weight. The presence of other molecules can create favorable or unfavorable molecular interactions with HA. The objective of the study was to investigate the effect of products, that are commonly associated with HA (corticosteroids, lidocain, iodinated contrast media), on the rheological behavior of HA, then to try drawing practical conclusions.

Methods: The rheological behavior of both a linear and a cross-linked HA, was studied before and after mixing with different volumes (ratio 1:0.5-1:4) of the following compounds: phosphate buffered saline (PBS, as a control), cortivazol, triamcinolone hexacetonide, lidocain chlorhydrate and meglumine ioxaglate. The flow curve of the different samples was obtained using a measuring method based on a constant shear rate.

Results: Whatever the dilution and the added molecule were, viscosity of the cross-linked viscosupplement remained much higher than that of the linear one. Addition of PBS at a ratio 1:1 caused a dramatic decrease (up to 97.5 %) of HA viscosity. Cortivazol and lidocain had a similar effect than PBS on linear HA. Both were much deleterious on cross-linked HA viscosity. Among corticosteroids, triamcinolone decreased much less HA viscosity than cortivazol. The effect of meglumine ioxaglate was dose-dependent. Up to a ratio 1:1 viscosity of the linear HA remained above the dilution effect. On the cross-linked HA, the deleterious effect of the contrast agent was evident as soon as a ratio 1:1 and became very marked at 1:2.

Conclusion: HA viscosity varies widely in presence of other molecules. These changes are due to both dilution and molecular interactions. This study suggests that addition of other molecules with HA can lead to a major decrease of its viscosity. However, provided to respect a maximum ratio of 1:1, the contrast medium and triamcinolone seem to have no major deleterious effect on the viscosity level, especially on crosslinked HA. The study also suggests a deleterious effect of lidocain on the cross-linked HA. These in vitro data suggest that drugs associations must be avoided when they are not essential. However, clinical trials are needed to determine whether these rheological changes may have a significant impact on the clinical outcome.

Keywords: Contrast product; Cortivazol; Hyaluronic acid; Intra-articular corticosteroid; Ioxaglic acid; Lidocain; Rheology; Triamcinolone; Viscosupplementation.

Figures

Fig. 1
Fig. 1
Flow curve of linear hyaluronic acid diluted with increasing volumes of PBS. Viscosity is given in Pa.s according to the shear rate s−1. HA hyaluronic acid, PBS phosphate buffer saline
Fig. 2
Fig. 2
Flow curve of cross-linked hyaluronic acid diluted with increasing volumes of PBS. Viscosity is given in Pa.s according to the shear rate s−1. HA hyaluronic acid, PBS phosphate buffer saline
Fig. 3
Fig. 3
Flow curve of linear hyaluronic acid mixed with different products (ratio 1:1). HA hyaluronic acid, TH triamcinolone hexacetonide, IA ioxaglic acid, PBS phosphate buffer saline
Fig. 4
Fig. 4
Flow curve of cross-linked hyaluronic acid mixed with different products (ratio 1:1). HA hyaluronic acid, TH triamcinolone hexacetonide, IA ioxaglic acid, PBS phosphate buffer saline

Similar articles

See all similar articles

Cited by 3 articles

References

    1. Bagga H, Burkhardt D, Sambrook P, March L. Longterm effects of intraarticular hyaluronan on synovial fluid in osteoarthritis of the knee. J Rheumatol. 2006;33:946–950. - PubMed
    1. Bannuru RR, Natov NS, Obadan IE, Price LL, Schmid CH, McAlindon TE. Therapeutic trajectory of hyaluronic acid versus corticosteroids in the treatment of knee osteoarthritis: a systematic review and meta-analysis. Arthritis Rheum. 2009;61:1704–1711. doi: 10.1002/art.24925. - DOI - PubMed
    1. Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med. 2015;162:46–54. doi: 10.7326/M14-1231. - DOI - PubMed
    1. Bruyère Cooper C, Pelletier JP, Branco J, Brandi ML, Guillemin F, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) Semin Arthritis Rheum. 2014 - PubMed
    1. Conrozier T, Bossert M, Walliser-Lohse A, Bozgan AM, Balblanc JC. Viscosupplémentation par monoinjection d’acide hyaluronique + mannitol dans l’arthrose de la cheville: résultat d’un suivi standardisé chez 50 patients. Rev Rhum. 2014;81(suppl):A191.

LinkOut - more resources

Feedback